1. Search Result
Search Result
Pathways Recommended: Vitamin D Related/Nuclear Receptor
Results for "

vitamin D receptor (VDR)

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

3

Natural
Products

2

Recombinant Proteins

4

Isotope-Labeled Compounds

1

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103053

    VD/VDR Apoptosis Cancer
    PS121912 is a selective vitamin D receptor (VDR)-coregulator inhibitor. PS121912 has acceptable metabolic stability in vivo. PS121912 can be used for the research of cancer .
    PS121912
  • HY-76814

    VD/VDR Metabolic Disease
    Calcitriol-d6 is the deuterium labeled Calcitriol. Calcitriol is the active metabolite of vitamin D3 that activates the vitamin D receptor (VDR)[1].
    Calcitriol-d6
  • HY-10002
    Calcitriol
    Maximum Cited Publications
    44 Publications Verification

    1,25-Dihydroxyvitamin D3

    Drug Metabolite VD/VDR Endogenous Metabolite Cancer
    Calcitriol is the most active metabolite of vitamin D and also a vitamin D receptor (VDR) agonist.
    Calcitriol
  • HY-75041

    VD/VDR Metabolic Disease
    Calcitriol Impurities A is the impurity of Calcitriol, Calcitriol is the hormonally active form of vitamin D, Calcitriol is the active metabolite of vitamin D3 that activates the vitamin D receptor (VDR).
    Calcitriol Impurities A
  • HY-77274

    VD/VDR Metabolic Disease
    Calcitriol Impurities D is the impurity of Calcitriol, Calcitriol is the hormonally active form of vitamin D, Calcitriol is the active metabolite of vitamin D3 that activates the vitamin D receptor (VDR).
    Calcitriol Impurities D
  • HY-15329

    VD/VDR Metabolic Disease
    Maxacalcitol-d66 is the deuterated form of Maxacalcitol (22-Oxacalcitriol), which is a non-calcemic vitamin D3 analog and VDR ligand of VDR-like receptors.
    Maxacalcitol-d6
  • HY-10002S

    1,25-Dihydroxyvitamin D3-13C3

    Isotope-Labeled Compounds Sodium Channel Neurological Disease
    Calcitriol- 13C3 is the 13C-labeled Calcitriol. Calcitriol is the most active metabolite of vitamin D and also a vitamin D receptor (VDR) agonist.
    Calcitriol-13C3
  • HY-13293

    VD/VDR Cancer
    Impurity C of Calcitriol, Calcitriol(1,25-Dihydroxyvitamin D3; Rocaltrol ) is the hormonally active form of vitamin D, Calcitriol is the active metabolite of vitamin D3 that activates the vitamin D receptor (VDR).
    Impurity C of Calcitriol
  • HY-13292

    1β,25-Dihydroxyvitamin-D3; 1-Epicalcitriol

    VD/VDR Cancer
    Impurity B of Calcitriol, Calcitriol(1,25-Dihydroxyvitamin D3; Rocaltrol ) is the hormonally active form of vitamin D, Calcitriol is the active metabolite of vitamin D3 that activates the vitamin D receptor (VDR).
    Impurity B of Calcitriol
  • HY-10002R

    Drug Metabolite VD/VDR Endogenous Metabolite Cancer
    Calcitriol (Standard) is the analytical standard of Calcitriol. This product is intended for research and analytical applications. Calcitriol is the most active metabolite of vitamin D and also a vitamin D receptor (VDR) agonist.
    Calcitriol (Standard)
  • HY-107218

    RAR/RXR VD/VDR Infection
    11-Hydroxysugiol regulates the SUMOylation of intracellular receptors by modulating RARα and vitamin D3 receptor (VDR) .
    11-Hydroxysugiol
  • HY-10002S1

    1,25-Dihydroxyvitamin D3-d3

    VD/VDR Endogenous Metabolite Cancer
    Calcitriol-d3 is the deuterium labeled Calcitriol[1]. Calcitriol is the most active metabolite of vitamin D and also a vitamin D receptor (VDR) agonist[2][3][4][5].
    Calcitriol-d3
  • HY-147337
    MeTC7
    1 Publications Verification

    VD/VDR Cancer
    MeTC7 is a Vitamin-D receptor (VDR) antagonist. MeTC7 has potent VDR inhibition activity with an IC50 value of 2.9 μM. MeTC7 shows good antitumor effects .
    MeTC7
  • HY-149899

    VD/VDR Others
    VDR agonist 2 (compound 16i) is a VDR (vitamin D receptor) agonist that can effectively inhibit TGF-β1-induced activation of hepatic stellate cells (HSC). VDR agonist 2 has significant anti-hepatic fibrosis effects both in vitro and in vivo .
    VDR agonist 2
  • HY-114310

    VD/VDR Apoptosis Cancer
    VDR agonist 1 (compound 28) is a nonsteroidal Vitamin D receptor (VDR) agonist, with an IC50 of 690 nM in MCF-7 cells. VDR agonist 1 arrests the cell cycle through the up-regulation of p21 and p27, promotes apoptosis by increasing the expression of BAX and decrease the expression of Bcl-2 .
    VDR agonist 1
  • HY-117182

    Apoptosis VD/VDR RAR/RXR Metabolic Disease Inflammation/Immunology Cancer
    LG190178 is a non-steroidal vitamin D receptor (VDR) ligand that can induce the formation of heterodimer complexes between VDR and retinoid X receptor (RXR), stabilizing the agonistic conformation of the VDR ligand-binding domain and promoting its interaction with co-activators. LG190178 has functions in regulating calcium homeostasis, bone mineralization, as well as cell proliferation, differentiation, and apoptosis, making it useful for research in psoriasis, osteoporosis, and cancer .
    LG190178
  • HY-32345

    BXL-628; Ro-26-9228

    VD/VDR Inflammation/Immunology Cancer
    Elocalcitol (BXL-628) is a selective, orally active vitamin D receptor (VDR) agonist. Elocalcitol shows anti-inflammatory activity. Elocalcitol inhibits growth of prostate cancer cells .
    Elocalcitol
  • HY-12398A
    TEI-9648
    1 Publications Verification

    VD/VDR Metabolic Disease Inflammation/Immunology
    TEI-9648, a Vitamin D3 Lactone analogue, is a potent and specific vitamin D receptor (VDR) antagonist. TEI-9648 inhibits VDR/VDRE-mediated genomic actions of 1α,25(OH)2D3. TEI-9648 also inhibits HL-60 cell differentiation induced by of 1α,25(OH)2D3. TEI-9648 has the potential for bone metabolism research .
    TEI-9648
  • HY-14863

    CTA-018

    VD/VDR Cytochrome P450 Others Endocrinology
    Lunacalcipol (CTA-018), as a vitamin D analogue, has a dual role in the pathogenesis of Chronic Kidney Disease (CKD), as an agonist of vitamin D receptor and an antagonist of cytochrome P450 enzyme 24-hydroxylase. Lunacalcipol binds to VDR and regulates transcriptional activity of VDR by influencing ligand binding affinity, ligand-dependent coactivator recruitment or inhibitory factor dissociation, efficiency of ligand entry into target cells, tissue specificity and different metabolism of ligand. Lunacalcipol can be used in the study of CKD, especially Secondary Hyperparathyroidism (sHPT) .
    Lunacalcipol
  • HY-12398
    TEI-9647
    1 Publications Verification

    VD/VDR Metabolic Disease Inflammation/Immunology
    TEI-9647, a Vitamin D3 Lactone analogue, is a potent and specific vitamin D receptor (VDR) antagonist. TEI-9647 inhibits VDR/VDRE-mediated genomic actions of 1α,25(OH)2D3. TEI-9647 inhibits bone resorption and HL-60 cell differentiation induced by of 1α,25(OH)2D3. TEI-9647 has the potential for suppressing the excessive bone resorption and osteoclast formation in Paget's disease .
    TEI-9647
  • HY-32344
    Inecalcitol
    1 Publications Verification

    TX 522

    VD/VDR Apoptosis Cancer
    Inecalcitol (TX 522), a unique vitamin D3 analog, is an orally active vitamin D receptor (VDR) agonist with a Kd of 0.53 nM. Inecalcitol can induce cell apoptosis and has potent anticancer activities . Inecalcitol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Inecalcitol
  • HY-77278

    VD/VDR Aryl Hydrocarbon Receptor LXR PPAR Others
    25-Hydroxytachysterol3 is the metabolite of Vitamin D3 (HY-15398). 25-Hydroxytachysterol3 inhibits the proliferation of epidermal keratinocytes and dermal fibroblasts, stimulates the expression of differentiation- and antioxidant-related genes in keratinocytes. 25-Hydroxytachysterol3 activates vitamin D receptor (VDR) and aryl hydrocarbon receptor (AhR), liver X receptor α/β (LXR α/β) and peroxisome proliferator-activated receptor γ (PPARγ), stimulates the expression of CYP24A1 .
    25-Hydroxytachysterol3
  • HY-10002A

    1α,25-Dihydroxy-3-epi-vitamin-D3

    VD/VDR Others
    (1S)-Calcitriol (1α,25-Dihydroxy-3-epi-vitamin-D3) is a natural metabolite of 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3). (1S)-Calcitriol exhibits potent vitamin D receptor (VDR)-mediated actions such as inhibition of keratinocyte growth or suppression of parathyroid hormone secretion .
    (1S)-Calcitriol
  • HY-32343
    Secalciferol
    4 Publications Verification

    (24R)-24,25-Dihydroxyvitamin D3

    Endogenous Metabolite VD/VDR Metabolic Disease Inflammation/Immunology
    Secalciferol ((24R)-24,25-Dihydroxyvitamin D3) is the major active metabolite of Vitamin D. Secalciferol activates vitamin D receptor (VDR) with an EC50 value of 150 nM. Secalciferol is involved in a wide range of biological functions such as calcium homeostasis, cellular differentiation and proliferation processes, as well as other functions related to the immune system, which is promising for research of rickets, osteomalacia, hypercalcemia and autoimmune disorders .
    Secalciferol
  • HY-12397
    ZK159222
    1 Publications Verification

    VD/VDR Endocrinology
    ZK159222, a 25-carboxylic ester analogue of 1α,25-(OH)2D3, is a potent 1α,25-(OH)2Dreceptor (VDR) antagonist. The mechanism of ZK159222 antagonistic action is mediated by a lack of ligand-induced vitamin D receptor interaction with coactivators. ZK159222 has a partial agonistic character .
    ZK159222
  • HY-B1844

    Others Cancer
    Flucythrinate is a synthetic pyrethroid with endocrine suppressive properties. Flucythrinate showed good binding affinity to the vitamin D nuclear receptor (VDR) with a score of -11.0 kcal/mol. Flucythrinate has been proposed as a multi-target ligand that may interact with several proteins associated with breast cancer. The screening method for Flucythrinate showed good accuracy in binding site prediction and affinity estimation .
    Flucythrinate
  • HY-161778

    HDAC VD/VDR Inflammation/Immunology Cancer
    ZG-126 is an agonist for vitamin D receptor (VDR) and an inhibitor for histone deacetylase (HDAC) (IC50=0.63-67.6 μM). ZG-126 exhibits cytotoxicity in cancer cells MDA-MB-231 and 4T1. ZG-126 exhibits antitumor and anti-metastatic efficacy against melanoma and triple-negative breast cancer (TNBC) in mouse models. ZG-126 also exhibits anti-inflammatory activity, through the reduction of macrophage infiltration and immunosuppressive M2-polarization .
    ZG-126

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: